

SB 1528 A STAFF MEASURE SUMMARY

House Committee On Rules

Prepared By: Daniel Dietz

Meeting Dates: 3/2

WHAT THE MEASURE DOES:

The measure expands annual drug manufacturer reporting requirements to include information about all patient assistance programs (PAPs) beginning January 1, 2028.

Detailed Summary:

Specifies that drug manufacturers must include, within prescription drug price transparency reports to the Department of Consumer and Business Services (DCBS), specified information about all PAPs that service Oregon consumers, including for drugs that do not trigger price reporting thresholds. Requires reports to include the number of Oregon consumers who participated, eligibility criteria, the total value of assistance, and other specified information.

SENATE VOTE: Ayes, 17; Nays, 10.

Fiscal impact: Minimal fiscal impact

Revenue impact: No revenue impact

ISSUES DISCUSSED:

EFFECT OF AMENDMENT:

No amendment.

BACKGROUND:

Oregon's Prescription Drug Price Transparency program was established within DCBS by House Bill 4005 (2019). The program is required to report to the legislature by December 15 each year, including recommendations for legislative changes to contain the cost of prescription drugs and reduce the impact of price increases on consumers. In its [2025 report](#), the program makes five recommendations, including requiring manufacturers to report annually on all PAPs they maintain or fund, and centralizing state Medicaid drug purchasing to create cost savings.

Senate Bill 1528 A would require all drug manufacturers with PAPs serving Oregon consumers to report annually to DCBS beginning January 1, 2028.